# Retatrutide

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/retatrutide
Canonical HTML page: https://getbiobrief.com/entity/retatrutide

## Recent coverage (3 stories)

### RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse
2026-03-20 05:29:24 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
Full story: https://getbiobrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver

### Lilly’s Retatrutide Shows 1.9% A1c Drop, Trailing Mounjaro in Phase 3
2026-03-19 11:58:23 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Full story: https://getbiobrief.com/story/lilly-retatrutide-phase-3-diabetes-data

### Novo Nordisk Triple-G Agonist Hits 20% Weight Loss in Phase 2 Trial
2026-02-24 12:08:43 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Novo Nordisk's experimental triple-G agonist demonstrated nearly 20% weight loss in a 26-week Phase 2 trial, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's mid-stage results, Novo remains on track to reach the market after its rival.
Full story: https://getbiobrief.com/story/novo-nordisk-triple-g-obesity-trial-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.